Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children
Key facts
- Who runs it
- Materia Medica Holding
- Where
- Russia30 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 264 people, planned
- Started
- 3 Oct 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Rengalin
- Placebo
- Record updated
- 13 February 2026
Who can take part
- Age
- 6 months to 3 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Outpatients of both genders aged over 6 months and under 3 years
- Clinically confirmed diagnosis of acute viral upper respiratory tract infections (acute pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, tracheitis, acute viral respiratory infection of multiple and unspecified localization) during the epidemic growth of influenza and ARVI
- Dry (non-productive) cough lasting at least 24 hours but not more than 72 hours
- Total (day and night) cough severity score of 6 or more
- Availability of a patient information sheet and an informed consent form for participation in the clinical trial signed by one of the patient's parents/adoptive parents
Who cannot take part
- Taking medications listed in the section "Prohibited Concomitant Therapy" within 4 weeks prior to inclusion in the study
- Patients whose parents/adoptive parents, from the investigator's point of view, will not comply with observation requirements during the study or with the administration of study drugs
- Participation in other clinical trials within 3 months prior to inclusion in this trial
- Presence of the following diseases at the time of inclusion in the clinical trial:; 1.1 Inflammatory processes in the lower respiratory tract. 1.2 Grade III adenoid hypertrophy. 1.3 Chronic adenoiditis. 1.4 Postnasal drip syndrome. 1.5 Gastroesophageal reflux. 1.6 Bronchial asthma. 1.7 Cystic fibrosis. 1.8 Primary ciliary dyskinesia 1.9 Bronchopulmonary dysplasia 1.10 Malformations of the respiratory and ENT organs 1.11 Other chronic lung diseases. 1.12 Primary/secondary immunodeficiency. 1.13 Oncological disease of any localization
- Suspected bacterial infection of any localization, including pneumonia, sinusitis, otitis media
- Allergic rhinitis
- Bronchial obstruction syndrome
- Congenital heart defects with hypervolemia in pulmonary circulation
- Acute respiratory failure
- Inflammatory, degenerative, demyelinating diseases of the central nervous system, polyneuropathies, epilepsy
- Exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in a clinical trial
- Presence of allergy/hypersensitivity to any components of the medicines used in the treatment
- Acute obstructive laryngitis [croup] and epiglottitis
- A patient's parent/adoptive parent is related to on-site research personnel directly involved in the trial, or is the immediate family member of the investigator. 'Immediate family members' mean spouses, parents, children, or siblings, whether related or adopted
- The patient's parent/adoptive parent is employed by OOO "NPF "MATERIA MEDICA HOLDING", i.e., is an employee of the company, a temporary contract employee, or a designated official responsible for conducting the trial or their immediate family member
This trial is currently available in Russia.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the efficacy and safety of liquid dosage form of Rengalin in the treatment of cough in acute viral upper respiratory tract infections infections in children in during the epidemic growth of influenza and ARVI. The main questions it aims to answer are:
Read full original descriptionShow less
Investigators will compare the liquid dosage form of Rengalin to a placebo (a look-alike substance that contains no drug) to see if Rengalin in the liquid dosage form works for cough in acute viral upper respiratory tract infections in children.
Participants will:
Take the liquid dosage form of Rengalin or placebo per os 5 ml per administration 3 times a day for 7 days.
The 2 groups in the trial
- RengalinTreatment being tested
Orally. 5 ml per dose 3 times a day for 7 days. The drug is taken without meals.
- PlaceboPlacebo, for comparison
Placebo using the dosing regimen Rengalin for 7 days.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Rengalin in the Treatment of Cough in Acute Viral Upper Respiratory Tract Infections Tract Infections in Children During the Epidemic Growth of Influenza and ARVI
- Record updated
- 13 February 2026